Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality

The hallmarks of renal cell carcinoma (RCC) are angiogenesis and immunogenic tumor microenvironment. Over the past decades, treatment options for metastatic RCC (mRCC) have been expanding, from the inhibition of vessel formation via antiangiogenic agents (AAs) to the stimulation of immune system by...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaohan, Hou, Wanting, Gao, Ling, Shui, Lin, Yi, Cheng, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403214/
https://www.ncbi.nlm.nih.gov/pubmed/32850419
http://dx.doi.org/10.3389/fonc.2020.01321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403214/
https://www.ncbi.nlm.nih.gov/pubmed/32850419
http://dx.doi.org/10.3389/fonc.2020.01321

Ejemplares similares